Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The American Journal of Medicine
- The epidemiology of venous thromboembolism in the community.Arterioscler Thromb Vasc Biol. 2008; 28: 370-372
- A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study.Arch Intern Med. 1991; 151: 933-938
- Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association.Circulation. 2011; 123: 1788-1830
- 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.Eur Heart J. 2014; 35 (3069a-3069k): 3033-3069
- Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report.Chest. 2016; 149: 315-352
- Predictors of mortality from pulmonary embolism and their influence on clinical management.Thromb Haemost. 2008; 100: 747-751
- Massive pulmonary embolism.Circulation. 2006; 113: 577-582
- Accelerated thrombolysis for pulmonary embolism: will clinical benefit be ULTIMAtely realized?.Circulation. 2014; 129: 420-421
- A multidisciplinary pulmonary embolism response team: initial 30-month experience with a novel approach to delivery of care to patients with submassive and massive pulmonary embolism.Chest. 2016; 150: 384-393
- A pulmonary embolism response team's initial 20 month experience treating 87 patients with submassive and massive pulmonary embolism.Vasc Med. 2018; 23: 65-71
- The Massachusetts General Hospital Pulmonary Embolism Response Team (MGH PERT): creation of a multidisciplinary program to improve care of patients with massive and submassive pulmonary embolism.Hosp Pract (1995). 2014; 42: 31-37
- Impact of pulmonary arterial clot location on pulmonary embolism treatment and outcomes (90 days).Am J Cardiol. 2017; 119: 802-807
- Advanced treatment strategies for acute pulmonary embolism, including thrombolysis and embolectomy.J Thromb Haemost. 2009; 7(suppl 1): 322-327
- Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER).Lancet. 1999; 353: 1386-1389
- Fibrinolysis for patients with intermediate-risk pulmonary embolism.N Engl J Med. 2014; 370: 1402-1411
- A comparison of patients diagnosed with pulmonary embolism who are ≥65 years with patients <65 years.Am J Cardiol. 2015; 115: 681-686
- Trends in the management and outcomes of acute pulmonary embolism: analysis from the RIETE Registry.J Am Coll Cardiol. 2016; 67: 162-170
- Thrombolytic therapy and outcome of patients with an acute symptomatic pulmonary embolism.J Thromb Haemost. 2012; 10: 751-759
- Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis.Eur Heart J. 2015; 36: 605-614
- Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis.JAMA. 2014; 311: 2414-2421
- Therapy and outcomes in massive pulmonary embolism from the Emergency Medicine Pulmonary Embolism in the Real World Registry.Am J Emerg Med. 2012; 30: 1774-1781
- Thrombolytic therapy and mortality in patients with acute pulmonary embolism.Arch Intern Med. 2008; 168: 2183-2190
- Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial.J Thromb Thrombolysis. 1995; 2: 227-229
Conflict of Interest: JAB is a consultant for Aralez, Astra Zeneca, Janssen, Sanofi, and BMS (modest); serves on the data safety and monitoring board for Bayer (modest); and has equity in EMX and Janacare (modest). JG is a board member of VIVA Physicians, a 501c3 not-for-profit education and research organization (modest). MRJ is a compensated advisor for Philips/Volcano and Venarum (modest), and an equity investor for Embolitech, Vascular Therapies, PQ Bypass, MC10, Jana Care, and Sano V (modest). CK has received grant funding (paid to his institution) from the National Institutes of Health, Janssen, Diagnostica Stago, Siemens Healthcare Diagnostics, and Boehringer-Ingelheim. KR is a consultant for Abbott Vascular, Cardinal Health, Cook, Thrombolex, Surmodics, Volcano/Philips, Amegen; is a consultant on the scientific advisory board with equity or stock options from Capture Vascular, Contego, Cruzar Systems, Endospan, Eximo, MD Insider, Micell, Shockwave, Silkroad Medical, Valcare, Thrombolex; has received equity or stock options for serving on advisory boards from PQ Bypass, Primacea, Capture Vascular, VORTEX, MD Insider, Micell, Shockwave, Cruzar Systems, Endospan, Eximo, Valcare, Contego (modest); has received research grant support to his institution from Atrium-Getinge, Inari Medical, National Institutes of Health, Lutonix-Bard (modest); and is a board member of the National PERT Consortium, a 501c3 non-for-profit education and research organization, and VIVA Physicians, a 501c3 not-for-profit education and research organization (modest). IW is on the scientific advisory board for Novate Medical. All other authors have no relevant disclosures.
Authorship: All authors had access to the data and a role in writing this manuscript.
ScienceDirectAccess this article on ScienceDirect
- Advanced Therapies for Massive Pulmonary EmbolismThe American Journal of MedicineVol. 131Issue 12
- PreviewThe report by Secemsky et al1 in this issue of The American Journal of Medicine illustrates the current management of pulmonary embolism at the Massachusetts General Hospital (MGH). A Pulmonary Embolism Response Team sees all patients in whom pulmonary embolism is diagnosed by computed tomography. The team manages these patients during their hospitalization and after discharge for up to 1 year.1